Drug Approvals

Revuforj: A New Treatment for Acute Leukemia

Revuforj: A New Treatment for Acute Leukemia

What is the name of the drug and what does it do? Revuforj (pronounced REV-you-forge), generic name revumenib, is a prescription medication used to treat adults and children aged 1 year and older with relapsed or refractory acute leukemia. This treatment is specifically for cases with a lysine methyltransferase 2A (KMT2A) gene translocation, a genetic abnormality...

Hympavzi: A New Treatment for Hemophilia

Hympavzi: A New Treatment for Hemophilia

What is the name of the drug and what does it do? Hympavzi (pronounced him-PAV-zee), generic name marstacimab-hncq, is a medicine used to reduce or prevent bleeding episodes in people with hemophilia A or B. This treatment is specifically for individuals aged 12 years and older who do not have inhibitors (antibodies) against factor VIII or factor IX. Was Approved on...

Orlynvah: A New Treatment for Uncomplicated Urinary Tract Infections

Orlynvah: A New Treatment for Uncomplicated Urinary Tract Infections

What is the name of the drug and what does it do? Orlynvah (pronounced OR-lin-vah), a combination of sulopenem etzadroxil and probenecid, is a medication used to treat uncomplicated urinary tract infections (uUTIs) in adult women. It is specifically prescribed when there are limited or no alternative oral antibiotics available. Orlynvah targets bacterial infections...

Wegovy® Oral Tablet: A New Daily Pill Option for Weight Management

Wegovy® Oral Tablet: A New Daily Pill Option for Weight Management

Wegovy® has already changed how obesity is treated through a once-weekly injection. Now, Wegovy is entering a new phase. In early January 2026, Wegovy will become the first available daily oral GLP-1 tablet for chronic weight management, offering a pill option alongside the existing injectable form. This approval marks an important step for people who prefer an oral...

Rezdiffra: A New Treatment for Nonalcoholic Steatohepatitis (NASH)

Rezdiffra: A New Treatment for Nonalcoholic Steatohepatitis (NASH)

What is it prescribed for? REZDIFFRA, approved on March 14, 2024, is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. What is the name of the drug and what does it do? Rezdiffra (pronounced rez-DIF-rah), (generic name: resmetirom), is a...

Exblifep: A New Treatment for Complicated Urinary Tract Infections

Exblifep: A New Treatment for Complicated Urinary Tract Infections

What is it prescribed for? EXBLIFEP, Approved on February 22, 2024, is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. What is the name of the drug and what does it do? Exblifep (pronounced ex-BLI-fep), (generic name: cefepime and...